Bacteria fend off invading viruses with molecular scissors that slice up viral DNA—a system called CRISPR that's become ...
Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, ...
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome ...
Platform data establish Modified DNA’s potential to overcome two of the barriers that have kept DNA from becoming a practical ...
Engage Bio’s Tethosome platform is designed to improve the potency, tolerability, and redosability of non-viral DNAAcquisition combines Engage’s innovative platform with Lilly’s broad genetic ...
Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...
RNA is the means of translating the genetic code embedded in DNA into proteins, which serve as enzymes, transporters, ...
I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...
A team of Rice University bioengineers has developed a new way to create highly realistic "mock" patient samples that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results